Pacira BioSciences Files 8-K on Operations & Financial Condition
Ticker: PCRX · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1396814
| Field | Detail |
|---|---|
| Company | Pacira Biosciences, Inc. (PCRX) |
| Form Type | 8-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K
TL;DR
**Pacira BioSciences just dropped an 8-K on its financials, get ready for potential stock movement.**
AI Summary
Pacira BioSciences, Inc. filed an 8-K on January 4, 2024, to report on its results of operations and financial condition. This filing, under Items 2.02 and 9.01, indicates that the company is providing an update on its financial performance. For investors, this matters because it signals that new financial information is being disclosed, which could impact the stock's valuation and future outlook, potentially leading to price movements.
Why It Matters
This filing indicates Pacira BioSciences is releasing new financial information, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: medium — The filing itself is routine, but the undisclosed financial results could contain either positive or negative news, creating uncertainty.
Analyst Insight
A smart investor would await the full financial details referenced in this 8-K before making any investment decisions, as this filing only signals an upcoming disclosure, not the disclosure itself.
Key Numbers
- 001-35060 — Commission File Number (Identifies Pacira BioSciences' registration with the SEC.)
- 51-0619477 — IRS Employer Identification No. (Unique tax identification for Pacira BioSciences.)
- $0.001 — par value per share (The nominal value of Pacira BioSciences' common stock.)
Key Players & Entities
- Pacira BioSciences, Inc. (company) — the registrant filing the 8-K
- January 4, 2024 (date) — the date of the earliest event reported and filing date
- Delaware (company) — state of incorporation for Pacira BioSciences, Inc.
- 001-35060 (dollar_amount) — Commission File Number
- 51-0619477 (dollar_amount) — IRS Employer Identification No.
- PCRX (company) — trading symbol for Pacira BioSciences, Inc.
- Nasdaq Global Select Market (company) — exchange where Pacira BioSciences, Inc. common stock is registered
Forward-Looking Statements
- Pacira BioSciences will release detailed financial results shortly after this 8-K. (Pacira BioSciences, Inc.) — high confidence, target: 2024-01-31
- The market will react to the specific financial figures once they are publicly disclosed. (PCRX stock price) — medium confidence, target: 2024-01-15
FAQ
What is the primary purpose of this 8-K filing by Pacira BioSciences, Inc.?
The primary purpose of this 8-K filing, dated January 4, 2024, is to report on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' under Item 2.02 and Item 9.01, respectively.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 4, 2024, which is also the date of the report.
What is the trading symbol and the exchange where Pacira BioSciences, Inc.'s common stock is registered?
Pacira BioSciences, Inc.'s common stock has the trading symbol PCRX and is registered on the Nasdaq Global Select Market.
What is the state of incorporation for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. is incorporated in Delaware, as stated in the filing.
What is the par value of Pacira BioSciences, Inc.'s common stock?
The common stock of Pacira BioSciences, Inc. has a par value of $0.001 per share.
Filing Stats: 496 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-01-04 17:02:42
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share PCRX Nasdaq Global Select Mar
Filing Documents
- pcrx-20240104.htm (8-K) — 25KB
- pcrx-2023revenuepressrelea.htm (EX-99.1) — 31KB
- pacirabiosciencesa01a.jpg (GRAPHIC) — 27KB
- 0001396814-24-000010.txt ( ) — 228KB
- pcrx-20240104.xsd (EX-101.SCH) — 2KB
- pcrx-20240104_lab.xml (EX-101.LAB) — 25KB
- pcrx-20240104_pre.xml (EX-101.PRE) — 13KB
- pcrx-20240104_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On January 4, 2024, Pacira BioSciences, Inc. issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release dated January 4, 2024. 104 Cover Page Interactive Data File (Formatted as Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PACIRA BIOSCIENCES, INC. (REGISTRANT) Dated: January 4, 2024 By: /s/ KRISTEN WILLIAMS Kristen Williams Chief Administrative Officer and Secretary